Vumon

Last updated on RxList: 12/8/2016
Vumon Side Effects Center

Last reviewed on RxList 4/12/2016

Vumon (teniposide) Injection is a cancer (antineoplastic) medication used in the treatment of acute lymphoblastic leukemia (blood cancer) in children. Common side effects of Vumon include:

  • nausea and vomiting (may be severe)
  • stomach pain
  • loss of appetite
  • diarrhea
  • constipation
  • drowsiness
  • pain/redness at the injection site
  • headache
  • dizziness
  • tiredness
  • weakness
  • temporary hair loss, or
  • mild skin rash

Dosage of Vumon is individualized. The medication is given by slow injection into a vein under physician supervision over at least 30 to 60 minutes, usually once or twice a week or as directed. Vumon may interact with "live" vaccines. Tell your doctor all medications and supplements you use and vaccines you recently received. Vumon is not recommended for use during pregnancy. It may harm a fetus. If you become pregnant or think you may be pregnant, tell your doctor. Both males and females using this drug should use birth control (e.g., birth control pills, condoms) during treatment. Consult your doctor to discuss birth control. It is unknown if this drug passes into breast milk. It may have undesirable effects on a nursing infant. Breastfeeding while using Vumon is not recommended.

Our Vumon (teniposide) Injection Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

SLIDESHOW

Skin Cancer Symptoms, Types, Images See Slideshow
Vumon Consumer Information

Get emergency medical help if you have signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have a serious side effect such as:

  • fever, chills, itching, body aches, flu symptoms, sores in your mouth and throat;
  • easy bruising, unusual bleeding (nose, mouth, vagina, or rectum), purple or red pinpoint spots under your skin;
  • pale skin, feeling light-headed or short of breath, rapid heart rate, trouble concentrating;
  • fast or pounding heartbeats, wheezing, chest tightness, trouble breathing;
  • severe headache, buzzing in your ears, anxiety, confusion, chest pain, uneven heartbeats;
  • pain, burning, irritation, or skin changes where the injection was given;
  • feeling like you might pass out; or
  • severe nausea and vomiting.

Less serious side effects may include:

  • mild headache;
  • drowsiness, dizziness, feeling tired or weak;
  • mild nausea, stomach pain, loss of appetite;
  • constipation, diarrhea;
  • temporary hair loss; or
  • mild skin rash.

This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Read the entire detailed patient monograph for Vumon (Teniposide)

Vumon Professional Information

SIDE EFFECTS

The table below presents the incidences of adverse reactions derived from an analysis of data contained within literature reports of 7 studies involving 303 pediatric patients in which VUMON was administered by injection as a single agent in a variety of doses and schedules for a variety of hematologic malignancies and solid tumors. The total number of patients evaluable for a given event was not 303 since the individual studies did not address the occurrence of each event listed. Five of these 7 studies assessed VUMON activity in hematologic malignancies, such as leukemia. Thus, many of these patients had abnormal hematologic status at start of therapy with VUMON and were expected to develop significant myelosuppression as an endpoint of treatment.

Single-Agent VUMON Summary of Toxicity for All Evaluable Pediatric Patients

Toxicity Incidence in Evaluable Patients (%)
Hematologic Toxicity
  Myelosuppression, nonspecified   75
  Leukopenia ( < 3,000 WBC/mcL) 89
  Neutropenia ( < 2,000 ANC/mcL) 95
  Thrombocytopenia ( < 100,000 plt/mcL) 85
  Anemia 88
Non-Hematologic Toxicity
  Mucositis 76
  Diarrhea 33
  Nausea/vomiting 29
  Infection 12
  Alopecia 9
  Bleeding 5
  Hypersensitivity reactions 5
  Rash 3
  Fever 3
  Hypotension/Cardiovascular 2
  Neurotoxicity < 1
  Hepatic dysfunction < 1
  Renal dysfunction < 1
  Metabolic abnormalities < 1

Hematologic Toxicity

VUMON, when used with other chemotherapeutic agents for the treatment of ALL, results in severe myelosuppression. Sepsis, sometimes fatal, may be a consequence of severe myelosuppression. Early onset of profound myelosuppression with delayed recovery can be expected when using the doses and schedules of VUMON necessary for treatment of refractory ALL, since bone marrow hypoplasia is a desired endpoint of therapy. The occurrence of acute non-lymphocytic leukemia (ANLL), with or without a preleukemic phase, has been reported in patients treated with VUMON in combination with other antineoplastic agents. (See PRECAUTIONS: Carcinogenesis, Mutagenesis, Impairment of Fertility.)

Gastrointestinal Toxicity

Nausea and vomiting are the most common gastrointestinal toxicities, having occurred in 29% of evaluable pediatric patients. The severity of this nausea and vomiting is generally mild to moderate.

Hypotension

Transient hypotension following rapid intravenous administration has been reported in 2% of evaluable pediatric patients. One episode of sudden death, attributed to probable arrhythmia and intractable hypotension, has been reported in an elderly patient receiving VUMON combination therapy for a non-leukemic malignancy.

No other cardiac toxicity or electrocardiographic changes have been documented. No delayed hypotension has been noted.

Allergic Reactions

Hypersensitivity reactions characterized by chills, fever, tachycardia, flushing, bronchospasm, dyspnea, rash, and blood pressure changes (hypertension or hypotension) have been reported to occur in approximately 5% of evaluable pediatric patients receiving intravenous VUMON. The incidence of hypersensitivity reactions to VUMON appears to be increased in patients with brain tumors and in patients with neuroblastoma.

Central Nervous System

Neurotoxicity has been reported, including severe cases of neuropathy, in patients receiving vincristine sulfate and VUMON concomitantly.

Acute central nervous system depression and hypotension have been observed in patients receiving investigational infusions of high-dose VUMON who were pretreated with antiemetic drugs. The depressant effects of the antiemetic agents and the alcohol content of the VUMON formulation may place patients receiving higher than recommended doses of VUMON at risk for central nervous system depression.

Alopecia

Alopecia, sometimes progressing to total baldness, was observed in 9% of evaluable pediatric patients who received VUMON as single-agent therapy. It was usually reversible.

Other Adverse Reactions

The following adverse reactions have been reported: headache, confusion, and asthenia. Headache and confusion were associated with hypersensitivity reactions.

Read the entire FDA prescribing information for Vumon (Teniposide)

© Vumon Patient Information is supplied by Cerner Multum, Inc. and Vumon Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.

Health Solutions From Our Sponsors